how many amino acids in semaglutide Overview of Tirzepatide and Structure of semaglutide (subcutaneous formulation)

The drug was developed for patients with a body mass index (BMI) of 25 or higher, reflecting body shape and weight characteristics common among domestic patients

The SEM 150 group showed moderate protective efficacy with persistent records of moderate loss of trabecular bone area up to a 1.7-fold increase compared to the osteoporotic group, almost normalized trabecular bone thickness without abnormal deformities, with a moderate increase of osteoblastic activity with the significant restoration of bone marrow cellular elements

But here's the thing - we're all different

If your BMI is less than 35, non-surgical weight loss is your best option